Tirofuse Injection 100ml

Side Effects of Tirofuse Injection 100ml

Bleeding, thrombocytopenia, bradycardia, dissection of the coronary artery, dizziness, oedema, pelvic pain, sweating, nausea, fever, headache, rashes. Potentially Fatal: Anaphylaxis.

Drug Interactions

Potentially Fatal: Increased risk of bleeding with drugs that affect haemostasis including anticoagulants, thrombolytics, other glycoprotein IIb/IIIa inhibitors, platelet aggregation inhibitors (e.g. iloprost).

Contraindications

History of thrombocytopenia with glycoprotein IIb/IIIa receptor antagonist. Active internal bleeding. Active peptic ulcer within the past 3 mth. History of bleeding diathesis within the previous 30 days; history of stroke within 30 days or history of intracranial haemorrhage; history or findings suggestive of aortic dissection; intracranial neoplasm, arteriovenous malformation, or aneurysm; acute pericarditis; vasculitis; haemorrhagic retinopathy; uncontrolled hypertension >180/110 mm Hg; anaemia. Recent major surgery or severe trauma. Traumatic or protracted CPR, organ biopsy or lithotripsy within the past 2 wk. Serious hepatic impairment.

Mechanism of Action

Tirofiban, a synthetic nonpeptide tyrosine derivative, is a platelet glycoprotein (GP IIb/IIIa)-receptor inhibitor. It reversibly inhibits binding of fibrinogen to the glycoprotein IIb/IIIa receptors of platelets. Duration: 4-8 hr. Distribution: Plasma half-life: 2 hr. Protein-binding: 65%. Volume of distribution: 22-42 L. Metabolism: Limited metabolism. Excretion: Eliminated largely unchanged in the urine, with some biliary excretion in the faeces.

Special Precautions

Anaemia, thrombocytopenia or known history of platelet function disturbance. Puncture of a non-compressible vessel within 24 hr, recent epidural procedure, severe CHF, cardiogenic shock. Discontinue in case of uncontrolled bleeding or require emergency surgery or thrombolytic therapy. Severe renal impairment. Monitor platelet counts, haematocrit and haemoglobin before and periodically (e.g. within the first 6 hr of the loading infusion and daily thereafter). Monitor activated clotting time (ACT) or aPTT if on concurrent heparin therapy. Defer PCI for at least 4 hr after initiation of therapy. Elderly, females, patients with low body weight.

How to Use

Take orally with food and water, as directed by your physician.

How to Store

Keep in a cool, dry place away from sunlight and moisture.

Safety Concerns

• Alcohol: Avoid during treatment.
• Breastfeeding: Not recommended.
• Pregnancy: Contraindicated.
• Liver/Kidney: Use with caution.

Content Disclaimer

This content is for educational purposes only. Please consult your doctor before use.